Comment
. 2008 Dec 4;359(23):2497-8; author reply 2498-9.
doi: 10.1056/NEJMc081780.
Sorafenib in advanced hepatocellular carcinoma
- PMID: 19052134
- DOI: 10.1056/NEJMc081780
Item in Clipboard
Comment
Sorafenib in advanced hepatocellular carcinoma
N Engl J Med.
.
No abstract available
Comment on
-
Sorafenib in advanced hepatocellular carcinoma.N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Clinical Trial.
-
Sorafenib in liver cancer--just the beginning.N Engl J Med. 2008 Jul 24;359(4):420-2. doi: 10.1056/NEJMe0802241. N Engl J Med. 2008. PMID: 18650519 No abstract available.
Similar articles
-
[Hepatocellular carcinoma - long-term treatable disease].Klin Onkol. 2012;25(4):287-9. Klin Onkol. 2012. PMID: 22920170 Czech.
-
Target therapy for hepatocellular carcinoma: is sorafenib for everybody?J Clin Gastroenterol. 2009 May-Jun;43(5):389-90. doi: 10.1097/MCG.0b013e31819eb9a6. J Clin Gastroenterol. 2009. PMID: 19564813 No abstract available.
-
Sorafenib-induced destructive thyroiditis.Thyroid. 2010 Sep;20(9):1043-4. doi: 10.1089/thy.2010.0070. Thyroid. 2010. PMID: 20825302 No abstract available.
-
Sorafenib: in hepatocellular carcinoma.Drugs. 2008;68(2):251-8. doi: 10.2165/00003495-200868020-00007. Drugs. 2008. PMID: 18197728 Review.
-
Sorafenib in hepatocellular carcinoma.Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669. Br J Hosp Med (Lond). 2010. PMID: 20852487 Review.
Cited by
-
Methodological assessment of HCC literature.Ann Oncol. 2013 Apr;24 Suppl 2(Suppl 2):ii6-14. doi: 10.1093/annonc/mdt052. Ann Oncol. 2013. PMID: 23715943 Free PMC article. Review.
-
Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment.Cancer Cell Int. 2022 Feb 11;22(1):73. doi: 10.1186/s12935-021-02435-4. Cancer Cell Int. 2022. PMID: 35148789 Free PMC article. Review.
-
Knockdown of Obg-like ATPase 1 enhances sorafenib sensitivity by inhibition of GSK-3β/β-catenin signaling in hepatocellular carcinoma cells.J Gastrointest Oncol. 2022 Jun;13(3):1255-1265. doi: 10.21037/jgo-22-458. J Gastrointest Oncol. 2022. PMID: 35837205 Free PMC article.
-
Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience.Ther Adv Med Oncol. 2023 Oct 24;15:17588359231206274. doi: 10.1177/17588359231206274. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37885459 Free PMC article.
-
Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.Biomed Res Int. 2014;2014:384121. doi: 10.1155/2014/384121. Epub 2014 May 7. Biomed Res Int. 2014. PMID: 24895573 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
